Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Alphamab Oncology FCF Yield % Related Terms
Alphamab Oncology FCF Yield % Historical Data
* Premium members only.
The historical data trend for Alphamab Oncology's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3NK vs VRTX, REGN, RVMD: FCF Yield % Comparison
For the Biotechnology subindustry, Alphamab Oncology's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology (FRA:3NK) has a FCF Yield % of -2.09 as of Aug. 20, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Alphamab Oncology and its competitors. According to the industry distribution chart, Alphamab Oncology ranks #359 out of 1410 companies in the Biotechnology industry, placing it in the top 25.5%.
Is Alphamab Oncology's FCF Yield % too high?
Alphamab Oncology's current FCF Yield % is -2.09. Based on the distribution chart, Alphamab Oncology ranks #359 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alphamab Oncology has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alphamab Oncology ranks #359 out of 1410 companies for FCF Yield %. This puts Alphamab Oncology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Alphamab Oncology and its competitors. Alphamab Oncology's current FCF Yield % is -2.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Alphamab Oncology (FRA:3NK) has a current FCF Yield % of -2.09. The stock's GF Value™ is €0.82, compared to a current price of €0.88 — trading 7.3% above its estimated fair value. The current FCF Yield % is -2.09. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Alphamab Oncology (FRA:3NK), the current FCF Yield % is -2.09 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (FRA:3NK) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of €0.88 is trading 7.3% above its estimated GF Value™ of €0.82.
Key valuation signals for FRA:3NK:
FCF Yield %: -2.09
GF Value™: €0.82 vs. price of €0.88 (7.3% above fair value)
No single metric tells the full story. See the FRA:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score
Get the complete analysis for FRA:3NK
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3NK has been successfully added to your 
